Devices not on FDA's agenda for MRA (mutual recognition agreement) meeting:
This article was originally published in Clinica
Executive Summary
The FDA's first public meeting to discuss progress in implementing the mutual recognition agreement (MRA) between the US and the European Union will focus on the agreement as it relates to pharmaceuticals, and not medical devices. The agency initially wanted to discuss the medical device sectoral annex and the drugs sectoral annex of the accord at its December 8 meeting but changed its mind because of differences between the two, according to Charles Gaylord in the FDA office of international and constituent relations. No date has been set for a public meeting on the section of the agreement covering devices, but it will probably take place within a few months, he said.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.